Additionally, NfL levels do not provide information on the specific location of axonal damage (Disanto et al., 2017), and a growing body of evidence has shown that NfL is also elevated in individuals with peripheral nerve disease (Sandelius et al., 2018; Hyun et al., 2020), which further limits its use as a diagnostic biomarker. This evidence concerns the gene NEFL and peripheral nervous system disorder.